“Our findings reveal how changes in cell metabolism and increased oxidative stress can activate damaging pathways in blood vessels," explained Xiaofeng Yang, MD, a researcher at Temple University.

Treatment with the device is consistently safe, but researchers still think more data is required before reaching any conclusions about its efficacy. 

Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

The first coronary DCB to gain FDA approval just received an additional reimbursement that could improve patient access. 

Study shows same-day discharge is feasible for carefully selected, uncomplicated ACS patients. 

Researchers explored data from thousands of U.S. veterans with coronary artery disease, sharing their findings in Circulation.

Prior studies have already evaluated how individual drinks affect the heart—but what about a person's beverage choices over an extended period of time?

John Puskas, MD, chief of cardiothoracic surgery at Emory University Hospital Midtown, noted that both treatment options have their own benefits. It often depends on the patient's age and comorbidities, though there are other factors to consider as well.